TLR agonist combinations that stimulate Th type I polarizing responses from human neonates

Innate Immunity

Volumn 24, Issue 4, 2018, Pages 240-251

  Surendran, Naveen ^a   Simmons, Andrea ^a   Pichichero, Michael E ^a  

^a ROCHESTER GENERAL HOSPITAL   (United States)

Author keywords

IFN ; IL 12; Neonatal innate immunity; neonatal vaccines; TLR synergy

Indexed keywords

ALPHA INTERFERON; CD40 ANTIGEN; CD83 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 6; PHOSPHORYL LIPID A; PROGRAMMED DEATH 1 LIGAND 1; RESIQUIMOD; TUMOR NECROSIS FACTOR; CYTOKINE; IMMUNOLOGICAL ADJUVANT; TOLL LIKE RECEPTOR; VACCINE;

ADULT; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOKINE RESPONSE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INNATE IMMUNITY; MONONUCLEAR CELL; NEWBORN; PROTEIN EXPRESSION; TH1 CELL; UMBILICAL CORD BLOOD; VACCINATION; AGONISTS; ANTIGEN PRESENTING CELL; BLOOD; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; VACCINE IMMUNOGENICITY;

ADJUVANTS, IMMUNOLOGIC; ANTIGEN-PRESENTING CELLS; CYTOKINES; HUMANS; IMMUNOGENICITY, VACCINE; INFANT, NEWBORN; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; TH1 CELLS; TOLL-LIKE RECEPTORS; VACCINES;

EID: 85047553318     PISSN: 17534259     EISSN: 17534267     Source Type: Journal    
DOI: 10.1177/1753425918771178     Document Type: Article

References (53)

1. WHO. Neonatal Mortality Rate (SDG 3.2.2). In: The Global Strategy for Women’s, Children’s and Adolescents’ Health (2016–2030). Report, WHO, 2015
2. Mohr E, Siegrist CA. Vaccination in early life: standing up to the challenges. Curr Opin Immunol 2016; 41: 1–8.
3. Morris MC, Surendran N. Neonatal vaccination: challenges and intervention strategies. Neonatology 2016; 109: 161–169.
4. Basha S, Surendran N, Pichichero M. Immune responses in neonates. Expert Rev Clin Immunol 2014; 10: 1171–1184.
5. Burl S, Townend J, Njie-Jobe J, Age-dependent maturation of Toll-like receptor-mediated cytokine responses in Gambian infants. PLoS One 2011; 6: e18185–e18185.
6. Corbett NP, Blimkie D, Ho KC, Ontogeny of Toll-like receptor mediated cytokine responses of human blood mononuclear cells. PLoS One 2010; 5: e15041–e15041.
7. Goriely S, Van Lint C, Dadkhah R, A defect in nucleosome remodeling prevents IL-12(p35) gene transcription in neonatal dendritic cells. J Exp Med 2004; 199: 1011–1016.
8. Kollmann TR, Crabtree J, Rein-Weston A, Neonatal innate TLR-mediated responses are distinct from those of adults. J Immunol 2009; 183: 7150–7160.
9. Lee HH, Hoeman CM, Hardaway JC, Delayed maturation of an IL-12-producing dendritic cell subset explains the early Th2 bias in neonatal immunity. J Exp Med 2008; 205: 2269–2280.
10. Levy O. Innate immunity of the newborn: basic mechanisms and clinical correlates. Nat Rev Immunol 2007; 7: 379–390.
11. Nguyen M, Leuridan E, Zhang T, Acquisition of adult-like TLR4 and TLR9 responses during the first year of life. PLoS One 2010; 5: e10407–e10407.
12. Willems F, Vollstedt S, Suter M. Phenotype and function of neonatal DC. Eur J Immunol 2009; 39: 26–35.
13. Zaghouani H, Hoeman CM, Adkins B. Neonatal immunity: faulty T-helpers and the shortcomings of dendritic cells. Trends Immunol 2009; 30: 585–591.
14. Upham JW, Rate A, Rowe J, Dendritic cell immaturity during infancy restricts the capacity to express vaccine-specific T-cell memory. Infect Immun 2006; 74: 1106–1112.
15. Van den Biggelaar AH, Prescott SL, Roponen M, Neonatal innate cytokine responses to BCG controlling T-cell development vary between populations. J Allergy Clin Immunol 2009; 124: 544–550, 550 e1–2.
16. Marchant A, Goetghebuer T, Ota MO, Newborns develop a Th1-type immune response to Mycobacterium bovis bacillus Calmette-Guerin vaccination. J Immunol 1999; 163: 2249–2255.
17. Liu E, Law HK, Lau YL. BCG promotes cord blood monocyte-derived dendritic cell maturation with nuclear Rel-B up-regulation and cytosolic I kappa B alpha and beta degradation. Pediatr Res 2003; 54: 105–112.
18. Aaby P, Andersen A, Ravn H, Co-administration of BCG and diphtheria-tetanus-pertussis (DTP) vaccinations may reduce infant mortality more than the WHO-schedule of BCG first and then DTP. A re-analysis of demographic surveillance data from rural Bangladesh. EBioMedicine 2017; 22: 173–180.
19. Aaby P, Kollmann TR, Benn CS. Nonspecific effects of neonatal and infant vaccination: public-health, immunological and conceptual challenges. Nat Immunol 2014; 15: 895–899.
20. Ota MO, Vekemans J, Schlegel-Haueter SE, Influence of Mycobacterium bovis bacillus Calmette-Guerin on Ab and cytokine responses to human neonatal vaccination. J Immunol 2002; 168: 919–925.
21. Vekemans J, Amedei A, Ota MO, Neonatal bacillus Calmette-Guerin vaccination induces adult-like IFN-gamma production by CD4+ T lymphocytes. Eur J Immunol 2001; 31: 1531–1535.
22. Jang S, Uematsu S, Akira S, IL-6 and IL-10 induction from dendritic cells in response to Mycobacterium tuberculosis is predominantly dependent on TLR2-mediated recognition. J Immunol 2004; 173: 3392–3397.
23. Pompei L, Jang S, Zamlynny B, Disparity in IL-12 release in dendritic cells and macrophages in response to Mycobacterium tuberculosis is due to use of distinct TLRs. J Immunol 2007; 178: 5192–5199.
24. Dowling DJ, Levy O. Pediatric vaccine adjuvants: components of the modern vaccinologist’s toolbox. Pediatr Infect Dis J 2015; 34: 1395–1398.
25. Levy O, Zarember KA, Roy RM, Selective impairment of TLR-mediated innate immunity in human newborns: neonatal blood plasma reduces monocyte TNF-alpha induction by bacterial lipopeptides, lipopolysaccharide, and imiquimod, but preserves the response to R-848. J Immunol 2004; 173: 4627–4634.
26. Velilla PA, Rugeles MT, Chougnet CA. Defective antigen-presenting cell function in human neonates. Clin Immunol 2006; 121: 251–259.
27. Siegrist CA. Mechanisms by which maternal Abs influence infant vaccine responses: review of hypotheses and definition of main determinants. Vaccine 2003; 21: 3406–3412.
28. Fransen F, Boog CJ, Van Putten JP, Agonists of Toll-like receptors 3, 4, 7, and 9 are candidates for use as adjuvants in an outer membrane vaccine against Neisseria meningitidis serogroup B. Infect Immun 2007; 75: 5939–5946.
29. Philbin VJ, Dowling DJ, Gallington LC, Imidazoquinoline Toll-like receptor 8 agonists activate human newborn monocytes and dendritic cells through adenosine-refractory and caspase-1-dependent pathways. J Allergy Clin Immunol 2012; 130: 195–204 e9.
30. Krumbiegel D, Zepp F, Meyer CU. Combined Toll-like receptor agonists synergistically increase production of inflammatory cytokines in human neonatal dendritic cells. Hum Immunol 2007; 68: 813–822.
31. Pihlgren M, Tougne C, Schallert N, CpG-motifs enhance initial and sustained primary tetanus-specific Ab secreting cell responses in spleen and bone marrow, but are more effective in adult than in neonatal mice. Vaccine 2003; 21: 2492–2499.
32. Higgins D, Rodriguez R, Milley R, Modulation of immunogenicity and allergenicity by controlling the number of immunostimulatory oligonucleotides linked to Amb a 1. J Allergy Clin Immunol 2006; 118: 504–510.
33. Lemoine S, Jaron B, Tabka S, Dectin-1 activation unlocks IL12A expression and reveals the TH1 potency of neonatal dendritic cells. J Allergy Clin Immunol 2015; 136: 1355–1368 e1–15.
34. Van Haren SD, Dowling DJ, Foppen W, Age-specific adjuvant synergy: dual TLR7/8 and Mincle activation of human newborn dendritic cells enables Th1 polarization. J Immunol 2016; 197: 4413–4424.
35. Napolitani G, Rinaldi A, Bertoni F, Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 2005; 6: 769–776.
36. Zhu Q, Egelston C, Gagnon S, Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. J Clin Invest 2010; 120: 607–616.
37. Jansen K, Blimkie D, Furlong J, Polychromatic flow cytometric high-throughput assay to analyze the innate immune response to Toll-like receptor stimulation. J Immunol Methods 2008; 336: 183–192.
38. Belderbos ME, Levy O, Meyaard L, Plasma-mediated immune suppression: a neonatal perspective. Pediatr Allergy Immunol 2013; 24: 102–113.
39. Gold MC, Donnelly E, Cook MS, Purified neonatal plasmacytoid dendritic cells overcome intrinsic maturation defect with TLR agonist stimulation. Pediatr Res 2006; 60: 34–37.
40. Wolfle SJ, Strebovsky J, Bartz H, PD-L1 expression on tolerogenic APCs is controlled by STAT-3. Eur J Immunol 2011; 41: 413–424.
41. Hornung V, Rothenfusser S, Britsch S, Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002; 168: 4531–4537.
42. Levy O, Suter EE, Miller RL, Unique efficacy of Toll-like receptor 8 agonists in activating human neonatal antigen-presenting cells. Blood 2006; 108: 1284–1290.
43. Casella CR, Mitchell TC. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol Life Sci 2008; 65: 3231–3240.
44. Longhi MP, Trumpfheller C, Idoyaga J, Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J Exp Med 2009; 206: 1589–1602.
45. Kawai T, Sato S, Ishii KJ, Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat Immunol 2004; 5: 1061–1068.
46. Colonna M, Trinchieri G, Liu YJ. Plasmacytoid dendritic cells in immunity. Nat Immunol 2004; 5: 1219–1226.
47. Gujer C, Sandgren KJ, Douagi I, IFN-alpha produced by human plasmacytoid dendritic cells enhances T cell-dependent naive B cell differentiation. J Leukoc Biol 2011; 89: 811–821.
48. Zhang X, Lepelley A, Azria E, Neonatal plasmacytoid dendritic cells (pDCs) display subset variation but can elicit potent anti-viral innate responses. PLoS One 2013; 8: e52003–e52003.
49. Gautier G, Humbert M, Deauvieau F, A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. J Exp Med 2005; 201: 1435–1446.
50. Kollmann TR, Levy O, Montgomery RR, Innate immune function by Toll-like receptors: distinct responses in newborns and the elderly. Immunity 2012; 37: 771–783.
51. Harper DM, Franco EL, Wheeler CM, Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367: 1247–1255.
52. Dowling DJ, Van Haren SD, Scheid A, TLR7/8 adjuvant overcomes newborn hyporesponsiveness to pneumococcal conjugate vaccine at birth. JCI Insight 2017; 2: e91020–e91020.
53. Eberhardt CS, Siegrist CA. What is wrong with pertussis vaccine immunity? Inducing and recalling vaccine-specific immunity. Cold Spring Harb Perspect Biol 2017; 9.